

# Bilateral versus single internal thoracic coronary artery bypass grafting: the ART RCT

Marcus Flather,<sup>1\*</sup> Arnaldo Dimagli,<sup>2,3</sup> Umberto Benedetto,<sup>2</sup> Belinda Lees,<sup>4</sup> Alastair Gray,<sup>5</sup> Stephen Gerry,<sup>6</sup> Ajita Naik,<sup>3</sup> Jo Cook,<sup>7</sup> Mario Gaudino,<sup>3</sup> Matthew Little<sup>5</sup> and David P Taggart<sup>4</sup>; on behalf of the ART Investigators

<sup>1</sup>Norwich Medical School, University of East Anglia and Norfolk and Norwich University Hospital, Norwich, UK

<sup>2</sup>School of Clinical Sciences, University of Bristol and Bristol Royal Infirmary, Bristol, UK

<sup>3</sup>Department of Cardiothoracic Surgery Weill Cornell Medicine New York – Presbyterian Hospital, New York, USA

<sup>4</sup>Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK

<sup>5</sup>Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK

<sup>6</sup>Centre for Statistics in Medicine, Botnar Research Centre, University of Oxford, Oxford, UK

<sup>7</sup>Surgical Intervention Trials Unit, Botnar Research Centre, University of Oxford, Oxford, UK

\*Corresponding author [m.flather@uea.ac.uk](mailto:m.flather@uea.ac.uk)

## Disclosure of interests of authors

**Full disclosure of interests:** Completed ICMJE forms for all authors, including all related interests, are available in the toolkit on the NIHR Journals Library report publication page at <https://doi.org/10.3310/JYGF5402>.

**Primary conflicts of interest:** None declared.

Published October 2023

DOI: 10.3310/JYGF5402

## Plain language summary

Bilateral versus single internal thoracic coronary artery bypass grafting: the ART RCT

Efficacy and Mechanism Evaluation 2023; Vol. 10: No. 7

DOI: 10.3310/JYGF5402

NIHR Journals Library [www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

# Plain language summary

## Introduction

Coronary artery bypass grafting is a surgical procedure aimed at improving blood flow in narrowed or blocked coronary (heart) arteries. The cardiac surgeon typically uses an artery from inside the chest wall (the internal thoracic artery) and veins from the leg to bypass the affected coronary arteries. Growing evidence suggests that using two internal thoracic arteries may be better than one. The main question in the Arterial Revascularisation Trial was 'would the use of two internal thoracic arteries allow patients to live longer after coronary artery bypass graft than those who received a single internal thoracic artery?'

## Methods

The Arterial Revascularisation Trial was carried out in 28 hospitals in 7 countries. Patients scheduled to have coronary artery bypass graft and willing to participate in the trial were allocated at random (like tossing a coin) to grafting with either a single or a double internal thoracic artery. Additional vein or arterial grafts were used as considered necessary for that patient. Patients enrolled into the Arterial Revascularisation Trial were then followed-up for 10 years.

## Results

A total of 3102 patients were enrolled in the trial; 1548 received bilateral internal thoracic artery and 1554 single internal thoracic artery grafts. Ninety-eight per cent of the patients were followed-up for up to 10 years and no statistical difference in survival was detected between the two groups at this timepoint (20.3% in the bilateral group vs. 21.2% in the single internal thoracic artery group). Additional analyses suggested that using more than one arterial graft, including the radial artery (from the arm), compared with using a single arterial graft, may be better, but this needs to be confirmed by further research.

## Limitations

Some patients received a single internal thoracic artery when they should have received bilateral internal thoracic arteries, which could have reduced the efficiency of the trial to detect a difference between the two groups.

## Discussion

The Arterial Revascularisation Trial is one of the largest long-term studies in cardiac surgery. This trial did not show that using two internal thoracic arteries during coronary artery bypass graft provides better outcomes for patients than using a single internal thoracic artery. Further results from the trial will be released upon completion of follow-up at 15 years.

# Efficacy and Mechanism Evaluation

ISSN 2050-4365 (Print)

ISSN 2050-4373 (Online)

*Efficacy and Mechanism Evaluation* (EME) was launched in 2014 and is indexed by Europe PMC, DOAJ, Ulrichsweb™ (ProQuest LLC, Ann Arbor, MI, USA) and NCBI Bookshelf.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) ([www.publicationethics.org/](http://www.publicationethics.org/)).

Editorial contact: [journals.library@nih.ac.uk](mailto:journals.library@nih.ac.uk)

The full EME archive is freely available to view online at [www.journalslibrary.nih.ac.uk/eme](http://www.journalslibrary.nih.ac.uk/eme).

## Criteria for inclusion in the *Efficacy and Mechanism Evaluation* journal

Reports are published in *Efficacy and Mechanism Evaluation* (EME) if (1) they have resulted from work for the EME programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

## EME programme

The Efficacy and Mechanism Evaluation (EME) programme funds ambitious studies evaluating interventions that have the potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care. Within these studies, EME supports research to improve the understanding of the mechanisms of both diseases and treatments.

The programme supports translational research into a wide range of new or repurposed interventions. These may include diagnostic or prognostic tests and decision-making tools, therapeutics or psychological treatments, medical devices, and public health initiatives delivered in the NHS.

The EME programme supports clinical trials and studies with other robust designs, which test the efficacy of interventions, and which may use clinical or well-validated surrogate outcomes. It only supports studies in man and where there is adequate proof of concept. The programme encourages hypothesis-driven mechanistic studies, integrated within the efficacy study, that explore the mechanisms of action of the intervention or the disease, the cause of differing responses, or improve the understanding of adverse effects. It funds similar mechanistic studies linked to studies funded by any NIHR programme.

The EME programme is funded by the Medical Research Council (MRC) and the National Institute for Health and Care Research (NIHR), with contributions from the Chief Scientist Office (CSO) in Scotland and National Institute for Social Care and Health Research (NISCHR) in Wales and the Health and Social Care Research and Development (HSC R&D), Public Health Agency in Northern Ireland.

## This report

The research reported in this issue of the journal was funded by the EME programme as project number 09/800/29. The contractual start date was in July 2004. The final report began editorial review in June 2022 and was accepted for publication in January 2023. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the MRC, the EME programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, the EME programme or the Department of Health and Social Care.

Copyright © 2023 Flather *et al.* This work was produced by Flather *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. See: <https://creativecommons.org/licenses/by/4.0/>. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

Published by the NIHR Journals Library ([www.journalslibrary.nih.ac.uk](http://www.journalslibrary.nih.ac.uk)), produced by Newgen Digitalworks Pvt Ltd, Chennai, India ([www.newgen.co](http://www.newgen.co)).

## NIHR Journals Library Editor-in-Chief

---

**Dr Cat Chatfield** Director of Health Services Research UK

## NIHR Journals Library Editors

---

**Professor Andrée Le May** Chair of NIHR Journals Library Editorial Group (HSDR, PGfAR, PHR journals) and Editor-in-Chief of HSDR, PGfAR, PHR journals

**Dr Peter Davidson** Interim Chair of HTA and EME Editorial Board, Consultant Advisor, School of Healthcare Enterprise and Innovation, University of Southampton, UK

**Professor Matthias Beck** Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

**Dr Tessa Crilly** Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin** Consultant in Public Health, Delta Public Health Consulting Ltd, UK

**Ms Tara Lamont** Senior Adviser, School of Healthcare Enterprise and Innovation, University of Southampton, UK

**Dr Catriona McDaid** Reader in Trials, Department of Health Sciences, University of York, UK

**Professor William McGuire** Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads** Emeritus Professor of Wellbeing Research, University of Winchester, UK

**Professor James Raftery** Professor of Health Technology Assessment, School of Healthcare Enterprise and Innovation, University of Southampton, UK

**Dr Rob Riemsma** Consultant Advisor, School of Healthcare Enterprise and Innovation, University of Southampton, UK

**Professor Helen Roberts** Professor of Child Health Research, Child and Adolescent Mental Health, Palliative Care and Paediatrics Unit, Population Policy and Practice Programme, UCL Great Ormond Street Institute of Child Health, London, UK

**Professor Jonathan Ross** Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks** Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Please visit the website for a list of editors: [www.journalslibrary.nihr.ac.uk/about/editors](http://www.journalslibrary.nihr.ac.uk/about/editors)

**Editorial contact:** [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)